Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
OTC Drugs

C&D First Response Innovations Respond To Consumer Feedback

This article was originally published in The Tan Sheet

  • News

Executive Summary

Church & Dwight is entering the digital pregnancy test market with First Response Early Result Gold Digital, an early-result test designed in part for easier use by non-English speakers, according to the firm

You may also be interested in...



Inverness Forced To Release Pregnancy Test Technology

Inverness Medical Innovations must clear a path for the introduction of a water-soluble dye technology for consumer pregnancy tests under a settlement with the Federal Trade Commission

Inverness Forced To Release Pregnancy Test Technology

Inverness Medical Innovations must clear a path for the introduction of a water-soluble dye technology for consumer pregnancy tests under a settlement with the Federal Trade Commission

Inverness Forced To Release Pregnancy Test Technology

Inverness Medical Innovations must clear a path for the introduction of a water-soluble dye technology for consumer pregnancy tests under a settlement with the Federal Trade Commission

Table

View full table

Topics

Tags:
OTC Drugs
Latest Headlines

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications

Industry & Regulators To Align Advice on COVID-19 Vaccine Updates

Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines

See All
UsernamePublicRestriction

Register

PS101541

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By